Abstract |
No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. METHODS: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient's data for survival including two clinical trials (BETA and ALFAE) was performed. RESULTS: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21-0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). CONCLUSIONS: Repeated doses of albumin might be beneficial for patient's survival as an add-on therapy after an HE episode, but an adequately powered trial is needed.
|
Authors | Meritxell Ventura-Cots, Macarena Simón-Talero, Maria Poca, Xavier Ariza, Helena Masnou, Jordi Sanchez, Elba Llop, Núria Cañete, Marta Martín-Llahí, Alberto Amador, Javier Martínez, Ana Clemente-Sanchez, Angela Puente, Maria Torrens, Edilmar Alvarado-Tapias, Laura Napoleone, Mireia Miquel-Planas, Alba Ardèvol, Meritxell Casas Rodrigo, Jose Luís Calleja, Cristina Solé, German Soriano, Joan Genescà |
Journal | Journal of clinical medicine
(J Clin Med)
Vol. 10
Issue 21
(Oct 23 2021)
ISSN: 2077-0383 [Print] Switzerland |
PMID | 34768404
(Publication Type: Journal Article)
|